TY - JOUR T1 - Lack of Relationship Between Clinical Features and <em>KRAS</em> Mutations in Patients with Metastatic Colorectal Cancer JF - Anticancer Research JO - Anticancer Res SP - 4233 LP - 4236 VL - 36 IS - 8 AU - ANNE PLOQUIN AU - FARID ZERIMECH AU - FABIENNE ESCANDE AU - ANTOINE ADENIS AU - CLAIRE GIRAUD AU - LAURENT GASNAULT AU - VINCENT BOURGEOIS AU - CHRISTOPHE DESAUW AU - MOHAMED HEBBAR Y1 - 2016/08/01 UR - http://ar.iiarjournals.org/content/36/8/4233.abstract N2 - Background/Aim: We previously identified three clinical predictive factors of efficacy of cetuximab-irinotecan. Here, we analyzed the clinical characteristics of patients with metastatic colorectal cancer (CRC) in order to detect potent correlations with KRAS mutations. Patients and Methods: We conducted a retrospective, multicenter study between 2008 and 2012. We included patients with metastatic colorectal adenocarcinomas, previously treated by irinotecan, and with an available KRAS mutation test. Results: We included 299 patients. The median age was 60 years; the median number of metastatic sites was 2. One hundred and eight patients (36.1%) had a previous objective response to irinotecan. The median interval between diagnosis and irinotecan discontinuation was 1.94 years. A KRAS mutation was detected in 133 patients (44.5%). In univariate and multivariate analyses, none of the assessed factors was associated with the presence of a KRAS mutation. Conclusion: No easily clinically assessable parameter was significantly associated with KRAS mutations in patients with colorectal cancer. ER -